In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Celgene (NASDAQ: CELG), with a price target of $140. The company’s shares opened today at $85.10, close to its 52-week low of $74.13.
According to TipRanks.com, Newman is a 5-star analyst with an average return of 19.4% and a 48.6% success rate. Newman covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Atara Biotherapeutics, and Gemphire Therapeutics.
Currently, the analyst consensus on Celgene is a Moderate Buy with an average price target of $119.15, implying a 40.0% upside from current levels. In a report issued on July 10, Oppenheimer also assigned a Buy rating to the stock with a $163 price target.
.
See today’s analyst top recommended stocks >>
Celgene’s market cap is currently $62.4B and has a P/E ratio of 24.21. The company has a Price to Book ratio of 12.06.
Based on the recent corporate insider activity of 53 insiders, corporate insider sentiment is neutral on the stock. Most recently, in May 2018, Gilla Kaplan, a Director at CELG sold 27,750 shares for a total of $2,182,538.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its targeting areas include intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The company’s products include Revlimid, Vidaza, Thalomid, Pomalyst/Imnovid, Abraxane, and Istodax. Celgene was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.
Read More on CELG:
